Table 1

Cohort demographics and culture data for baseline samples collected prior to the initiation of chronic TIP/S

Characteristics of patient cohortResponse*
Responder
(n=19) (46%)
Non-R†
(n=22) (54%)
P value
Female12 (63)11 (50)0.4
Median age, years (IQR)29.2 (24.2–38.6)30.4 (23.8–34.5)0.6
Median BMI (Kg/m2)22.1 (20.4–23.6)21.1 (19.3–22.4)0.3
Lung stage‡
 Forced expiratory volume (FEV) predicted50 (41–69)64 (48–83)0.2
 Mild5 (26)10 (45)0.4
 Moderate9 (47)8 (36)
 Severe5 (26)4 (18)
Genotype§
 ΔF508 homozygous9 (47)12 (55)0.5
 ΔF508 heterozygous7 (37)6 (27)0.4
CF comorbidities
 Pancreatic insufficiency15 (79)21 (95)0.1
 CF-related diabetes5 (26)7 (32)0.7
 Liver disease6 (32)3 (14)0.2
 Sinus disease5 (26)6 (27)0.9
Traditional cultured CF pathogens
Pseudomonas aeruginosa 19 (100)22 (100)>0.99
 Methicillin susceptible Staphylococcus aureus 6 (32)2 (9)0.07
 Methicillin resistant S. aureus 00NA
 Other¶2 (11)3 (14)0.8
  • X2 tests were used to determine differences between dichotomous clinical variables. Wilcoxon rank-sum tests were conducted for analysis of continuous variables.

  • *Response was a priori defined as achieving stable lung function as measured by FEV1 per cent predicted in the year following TIP/S initiation (no net decline).

  • †Non-R=non-responder.

  • ‡Definitions of lung stage based on forced expiratory volume in one second; mild ≥70%, moderate ≥40 to <70%, severe <40%.

  • §Genotypic data were unknown for one patient in the non-responder group.

  • ¶Other bacterial species include Escherichia coli, Enterobacter cloacae, Serratia marcescens, Streptococcus Group C, Stenotrophomonas maltophilia.

  • BMI, body mass index; CF, cystic fibrosis; NA, not applicable; TIP/S, tobramycin inhalational powder/solution.